Pharminent

Novartis looks earlier as biotech gets too expensive

The Swiss pharma is having trouble finding assets it likes to flesh out its pipeline as biotech valuations grow and its own earnings stay flat.  http://www.biopharmadive.com/news/novartis-looks-earlier-as-biotech-gets-too-expensive/441204/

Filed under: Company